BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22776546)

  • 21. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
    Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
    Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice.
    Arendash GW; Mori T; Cao C; Mamcarz M; Runfeldt M; Dickson A; Rezai-Zadeh K; Tane J; Citron BA; Lin X; Echeverria V; Potter H
    J Alzheimers Dis; 2009; 17(3):661-80. PubMed ID: 19581722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5).
    Ni W; Wang H; Li X; Zheng X; Wang M; Zhang J; Gong Q; Ling D; Mao F; Zhang H; Li J
    ACS Chem Neurosci; 2018 Jul; 9(7):1625-1636. PubMed ID: 29616790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
    Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
    Kloner RA
    Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
    Zhang L; Zhang Z; Zhang RL; Cui Y; LaPointe MC; Silver B; Chopp M
    Brain Res; 2006 Nov; 1118(1):192-8. PubMed ID: 16959227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
    Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
    Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
    Corbin JD; Francis SH
    Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice.
    García-Mesa Y; López-Ramos JC; Giménez-Llort L; Revilla S; Guerra R; Gruart A; Laferla FM; Cristòfol R; Delgado-García JM; Sanfeliu C
    J Alzheimers Dis; 2011; 24(3):421-54. PubMed ID: 21297257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model.
    Orejana L; Barros-Miñones L; Jordán J; Puerta E; Aguirre N
    Neurobiol Aging; 2012 Mar; 33(3):625.e11-20. PubMed ID: 21546125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
    J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gender differences in tail-skin flushing induced by nitrates and phosphodiesterase type 5 inhibitors in a climacteric mouse model.
    Sejima H; Tominaga K; Egawa T; Ikeda M; Shibuya K; Kameyama N; Yamauchi A; Shuto H; Kataoka Y
    Eur J Pharmacol; 2009 Dec; 624(1-3):66-70. PubMed ID: 19818343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
    Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
    J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sildenafil and tadalafil on ischemia/reperfusion injury in fetal rat brain.
    Ozdegirmenci O; Kucukozkan T; Akdag E; Topal T; Haberal A; Kayir H; Oter S; Akyol M; Uzbay T
    J Matern Fetal Neonatal Med; 2011 Feb; 24(2):317-23. PubMed ID: 20540678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels.
    Gómez-Vallejo V; Ugarte A; García-Barroso C; Cuadrado-Tejedor M; Szczupak B; Dopeso-Reyes IG; Lanciego JL; García-Osta A; Llop J; Oyarzabal J; Franco R
    J Neurochem; 2016 Jan; 136(2):403-15. PubMed ID: 26641206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
    Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
    Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.
    Arendash GW; Jensen MT; Salem N; Hussein N; Cracchiolo J; Dickson A; Leighty R; Potter H
    Neuroscience; 2007 Oct; 149(2):286-302. PubMed ID: 17904756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.